This is a working overview of research peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-26 and is reviewed periodically as new material appears.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Seth helps a very drunk Amber through her breakup with her fiancé, Ryan. It is shown that Seth is finally able to support himself with a job and house. He and Sarah chat later on about how he's doing over the phone. Seth sends Amber a baby crib to assemble once he discovers that she is pregnant.
== References == This article incorporates public domain material from websites or documents of the Centers for Disease Control and Prevention. This article incorporates public domain material from websites or documents of the United States Department of Health and Human Services.
The first total synthesis of phalloidin was achieved through a combination of solid phase and solution phase synthesis (Baosheng Liu and Jianheng Zhang, United States Patent, US 8,569,452 B2). The physical and chemical properties of the synthetic phalloidin are the same as the naturally occurring phalloidin.
In cardiology, the cardiac skeleton, also known as the fibrous skeleton of the heart, is a high-density homogeneous structure of connective tissue that forms and anchors the valves of the heart, and influences the forces exerted by and through them. The cardiac skeleton separates and partitions the atria (the smaller, upper two chambers) from the ventricles (the larger, lower two chambers). The heart's cardiac skeleton comprises four dense connective tissue rings that encircle the mitral and tricuspid atrioventricular (AV) canals and extend to the origins of the pulmonary trunk and aorta. This provides crucial support and structure to the heart while also serving to electrically isolate the atria from the ventricles. The unique matrix of connective tissue within the cardiac skeleton isolates electrical influence within these defined chambers. In normal anatomy, there is only one conduit for electrical conduction from the upper chambers to the lower chambers, known as the atrioventricular node. The physiologic cardiac skeleton forms a firewall governing autonomic/electrical influence until bordering the bundle of His which further governs autonomic flow to the bundle branches of the ventricles. Understood as such, the cardiac skeleton efficiently centers and robustly funnels electrical energy from the atria to the ventricles.
Sources: en.wikipedia.org
The Gam-COVID-Vac vaccine was developed by a cellular microbiologists team of the government-backed Gamaleya Research Institute of Epidemiology and Microbiology. The group was led by MD and RAS associate member Denis Logunov, who also worked on vaccines for the Ebolavirus and the MERS-coronavirus. In May 2020, the Gamaleya Research Institute of Epidemiology and Microbiology announced that it had developed the vaccine without serious side effects. By August 2020, phases I and II of two clinical trials (involving 38 patients each) were completed. Only one of them used the formulation which later obtained marketing authorization under limited conditions. This vaccine was given the trade name "Sputnik V", after the world's first artificial satellite. During preclinical and clinical trials, 38 participants who received one or two doses of the Gam-COVID-Vac vaccine had produced antibodies against SARS-CoV-2's spike protein, including potent neutralizing antibodies that inactivate viral particles. On 11 August 2020, the Russian minister of Health Mikhail Murashko announced at a government briefing with the participation of President Vladimir Putin regulatory approval of the vaccine for widespread use. The state registration of the vaccine was carried out "conditionally" with post-marketing measures according to the decree of the Government of the Russian Federation.
During HLF, koji-infused soybeans are exposed to air so that hydrolytic enzymes of the mold can continuously break down macronutrients within the soybean. Ample water, usually about 2 to 2.5 times the weight of the feed, is required to support sufficient microbial growth. High salt concentration (17–20%) is required to selectively inhibit microbial activity. HLF is generally carried out at 15–30 °C (59–86 °F), and requires a long ageing period, usually from 90 to 180 days. In the aging period, constant stirring of moromi (a mash/mixture of wheat (optionally), salt, soy beans, water, and fermenting yeast) is required for distributing nutrients, as well as flavoring compounds evenly. In some cases, moromi is exposed to direct sunlight to facilitate the decomposition of macronutrients. Due to the high salinity of HLF moromi, only anaerobic halophiles can survive in the medium. Also, the 15–30 °C (59–86 °F) temperature range allows only the growth of mesophiles. Similar to the fermentation of pickles, the primary lactic acid fermentation of sugars by halophiles reduces the pH of moromi down to acidic range. Low pH further limits the growth of undesirable microbes, but favors the growth of fermentative yeast which contributes to secondary fermentation that generates various flavoring compounds and odorants.
This method is also based on the large molecular weight and heat stability of endotoxins. Low molecular-weight solvents can be easily purified by boiling and collecting the condensed vapor in an endotoxin free vessel (see "heating" below). The large LPS molecules do not easily vaporize, and are thus left behind in the heating vessel. This is the method of choice for the purification of water.
== Match records == Highest score: 32.16 (208) v Footscray 9.8 (62) – Round 22, 1982, at Western Oval Lowest score: 0.9 (9) v Fitzroy 6.11 (47) – Round 1, 1899, at Brunswick Street Oval Lowest score since 1919: 1.12 (18) v St Kilda 5.5 (35) – Round 10, 1923, at Junction Oval Highest losing score: Essendon 21.13 (139) v Collingwood 23.6 (144), Round 22, 1987, M.C.G. Lowest winning score: Essendon 1.8 (14) v Melbourne 0.8 (8), Finals Week 3, 1897, Lake Oval (League record) Lowest winning score since 1919: Essendon 3.10 (28) v Footscray 3.5 (23), Round 13, 1989, Windy Hill Greatest winning margin: 165 points – Essendon 28.16 (184) v South Melbourne 2.7 (19), Round 18, 1964, Windy Hill Greatest losing margin: 163 points – Essendon 11.7 (73) v Sydney Swans 36.20 (236), Round 17, 1987, S.C.G. Record attendance (home-and-away game): 94,825 – 25 April 1995 at MCG v Collingwood (inaugural Anzac Day match) Record attendance (finals match): 116,828 – 1968 VFL Grand Final v Carlton
Ellen Jane Langer (; born March 25, 1947) is an American psychologist and professor of psychology at Harvard University. In 1981, she became the first woman to be tenured in psychology at Harvard. She has been called the "mother of mindfulness" and the "mother of positive psychology". Langer studies the illusion of control, decision-making, aging, and mindfulness theory. Her most influential work is Counterclockwise, published in 2009, the first test of her mind/body unity theory. Her most recent book, The Mindful Body: Thinking Our Way to Chronic Health, published in 2023, argues for the enormous control we have over our health based on mind/body unity.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.